Imaging pancreatic cancer with a peptide-nanoparticle conjugate targeted to normal pancreas

Bioconjugate Chemistry

Volumn 17, Issue 4, 2006, Pages 905-911

  Montet, Xavier ^a   Weissleder, Ralph ^a   Josephson, Lee ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORINE COMPOUNDS; DIAGNOSIS; DISEASES; INVERSE PROBLEMS; MAMMALS; NANOPARTICLES; SYNTHESIS (CHEMICAL); TARGETED DRUG DELIVERY; TISSUE;

ACINAR CELLS; BINDING RECEPTORS; DRUG DESIGN; DUCTAL ADENOCARCINOMAS; FLUORESCENCE MEASUREMENTS; NANOPARTICLE CONJUGATE; NORMAL TISSUE; PANCREATIC CANCERS; SYNTHESISED; VISUALIZATION METHOD;

PEPTIDES;

BOMBESIN; BOMBESIN RECEPTOR; CONTRAST MEDIUM; FLUORESCEIN; HAPTEN; NANOPARTICLE; PEPTIDE;

ACINAR CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DRUG ACCUMULATION; DRUG CONJUGATION; DRUG DESIGN; DRUG RECEPTOR BINDING; FEMALE; FLUORESCENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS; PANCREAS CANCER; PANCREATIC DUCTAL ADENOCARCINOMA; PEPTIDE SYNTHESIS; TARGET ORGAN;

EID: 33746771019     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc060035+     Document Type: Article

References (34)

1. Korner, M., Hayes, G. M., Rehmann, R., Zimmermann, A., Friess, H., Miller, L. J., and Reubi, J. C. (2005) Secretin receptors in normal and diseased human pancreas: marked reduction of receptor binding in ductal neoplasia. Am. J. Pathol. 167, 959-68.
2. Jensen, R. T., Wank, S. A., Rowley, W. H., Sato, S., and Gardner, J. D. (1989) Interaction of CCK with pancreatic acinar cells. Trends Pharmacol. Sci. 10, 418-23.
3. Reubi, J. C. (2000) In vitro evaluation of VIP/PACAP receptors in healthy and diseased human tissues. Clinical implications. Ann. N. Y. Acad. Sci. 921, 1-25.
4. Nock, B., Nikolopoulou, A., Chiotellis, E., Loudos, G., Maintas, D., Reubi, J. C., and Maina, T. (2003) [99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging. Eur. J. Nucl Med. Mol. Imaging 30, 247-58.
5. Reubi, J. C. (2003) Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr. Rev. 24, 389-427.
6. Reubi, J. C., and Waser, B. (2003) Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur. J. Nucl. Med. Mol. Imaging 30, 781-93.
7. Harisinghani, M. G., Barentsz, J., Hahn, P. F., Deserno, W. M., Tabatabaei, S., van de Kaa, C. H., de la Rosette, J., and Weissleder, R. (2003) Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N. Engl. J. Med. 348, 2491-9.
8. Chachuat, A., and Bonnemain, B. (1995) European clinical experience with Endorem. A new contrast agent for liver MRI in 1000 patients. Radiologe 35, S274-6.
9. Fleischmann, A., Laderach, U., Friess, H., Buechler, M. W., and Reubi, J. C. (2000) Bombesin receptors in distinct tissue compartments of human pancreatic diseases. Lab. Invest. 80, 1807-17.
10. Zachary, I., and Rozengurt, E. (1987) Internalization and degradation of peptides of the bombesin family in Swiss 3T3 cells occurs without ligand-induced receptor down-regulation. EMBO J. 6, 2233-9.
11. Zhu, W. Y., Goke, B., and Williams, J. A. (1991) Binding, internalization, and processing of bombesin by rat pancreatic acini. Am. J. Physiol. 261, G57-64.
12. Breeman, W. A., De Jong, M., Bernard, B. F., Kwekkeboom, D. J., Srinivasan, A., van der Pluijm, M. E., Hofland, L. J., Visser, T. J., and Krenning, E. P. (1999) Pre-clinical evaluation of [(111)In-DTPA-Pro(1), Tyr(4)]bombesin, a new radioligand for bombesin-receptor scintigraphy. Int. J. Cancer 83, 657-63.
13. Josephson, L., Tung, C. H., Moore, A., and Weissleder, R. (1999) High-efficiency intracellular magnetic labeling with novel super-paramagnetic- Tat peptide conjugates. Bioconjugate Chem. 10, 186-91.
14. Josephson, L., Ferez, J. M., and Weissleder, R. (2001) Magnetic nanosensors for the detection of oligonucleotide sequences. Angew. Chem., Int. Ed. 40, 3204-3206.
15. Koch, A. M., Reynolds, F., Kircher, M. F., Merkle, H. P., Weissleder, R., and Josephson, L. (2003) Uptake and metabolism of a dual fluorochrome Tat-nanoparticle in HeLa cells. Bioconjugate Chem. 14, 1115-21.
16. Reynolds, F., Weissleder, R., and Josephson, L. (2005) Protamine as an efficient membrane-translocating peptide. Bioconjugate Chem. 16, 1240-5.
17. Reynolds, F., O'Loughlin, T., Weissleder, R., and Josephson, L. (2005) Method of determining nanoparticle core weight. Anal. Chem. 77, 814-7.
18. Montet, X., Yuan, H., Weissleder, R., and Josephson, L. (2006) Enzyme based visualization of receptor-ligand binding in tissues. Lab. Invest. 86, 517-525.
19. Kelly, K. A., Reynolds, F., Weissleder, R., and Josephson, L. (2004) Fluorescein isothiocyanate-hapten immunoassay for determination of peptide-cell interactions. Anal. Biochem. 330, 181-5.
20. De Lisle, R. C., Logsdon, C. D., Hootman, S. R., and Williams, J. A. (1988) Monoclonal antibodies as probes for plasma membrane domains in the exocrine pancreas. J. Histochem. Cytochem. 36, 1043-51.
21. Sano, H., Feighner, S. D., Hreniuk, D. L., Iwaasa, H., Sailer, A. W., Pan, J., Reitman, M. L., Kanatani, A., Howard, A. D., and Tan, C. P. (2004) Characterization of the bombesin-like peptide receptor family in primates. Genomics 84, 139-46.
22. Xiao, D., Wang, J., Hampton, L. L., and Weber, H. C. (2001) The human gastrin-releasing peptide receptor gene structure, its tissue expression and promoter. Gene 264, 95-103.
23. Aharinejad, S., and Bock, P. (1994) Identification of fenestrated capillary segments in microvascular corrosion casts of the rat exocrine pancreas. Scanning 16, 209-14.
24. Zhou, J., Chen, J., Mokotoff, M., and Ball, E. D. (2004) Targeting gastrin-releasing peptide receptors for cancer treatment. Anticancer Drugs 15, 921-7.
25. Karra, S. R., Schibli, R., Gali, H., Katti, K. V., Hoffman, T. J., Higginbotham, C., Sieckman, G. L., and Volkert, W. A. (1999) 99mTc-labeling and in vivo studies of a bombesin analogue with a novel water-soluble dithiadiphosphine-based bifunctional chelating agent. Bioconjugate Chem. 10, 254-60.
26. Smith, C. J., Volkert, W. A., and Hoffman, T. J. (2003) Gastrin releasing peptide (GRP) receptor targeted radiopharmaceuticals: a concise update. Nucl. Med. Biol. 30, 861-8.
27. Rogers, B. E., Bigott, H. M., McCarthy, D. W., Della Manna, D., Kim, J., Sharp, T. L., and Welch, M. J. (2003) MicroPET imaging of a gastrin-releasing peptide receptor-positive tumor in a mouse model of human prostate cancer using a 64Cu-labeled bombesin analogue. Bioconjugate Chem. 14, 756-63.
28. Lin, K. S., Luu, A., Baidoo, K. E., Hashemzadeh-Gargari, H., Chen, M. K., Brenneman, K., Pili, R., Pomper, M., Carducci, M. A., and Wagner, H. N., Jr. (2005) A new high affinity technetium-99m-bombesin analogue with low abdominal accumulation. Bioconjugate Chem. 16, 43-50.
29. Van de Wiele, C., Dumont, F., Vanden Broecke, R., Oosterlinck, W., Cocquyt, V., Serreyn, R., Peers, S., Thornback, J., Siegers, G., and Dierckx, R. A. (2000) Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study. Eur. J. Nucl Med. 27, 1694-9.
30. Van de Wiele, C., Dumont, F., Dierckx, R. A., Peers, S. H., Thornback, J. R., Siegers, G., and Thierens, H. (2001) Biodistribution and dosimetry of (99m)Tc-RP527, a gastrin-releasing peptide (GRP) agonist for the visualization of GRP receptor-expressing malignancies. J. Nucl. Med. 42, 1722-7.
31. De Vincentis, G., Remediani, S., Varvarigou, A. D., Di Santo, G., Iori, F., Laurenti, C., and Scopinaro, F. (2004) Role of 99mTc-bombesin scan in diagnosis and staging of prostate cancer. Cancer Biother. Radiopharm. 19, 81-4.
32. Scopinaro, F., Varvarigou, A., Ussof, W., De Vincentis, G., Archimandritis, S., Evangelatos, G., Corleto, V., Pulcini, A., Capoccetti, F., Remediani, S., and Massa, R. (2002) Breast cancer takes up 99mTc bombesin. A preliminary report. Tumori 88, S25-8.
33. Syrigos, K. N., Vile, R. G., Peters, A. M., and Harrington, K. J. (2003) Biodistribution and pharmacokinetics of 111In-dTPA-labeled pegylated liposomes after intraperitoneal injection. Acta Oncol. 42, 147-53.
34. Armstrong, D. K., Bundy, B., Wenzel, L., Huang, H. Q., Baergen, R., Lele, S., Copeland, L. J., Walker, J. L., and Burger, R. A. (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354, 34-43.